In summary, this meta-analysis provides sensitive and specific diagnostic roles of KRAS and GNAS mutations for detecting the IPMN among the pancreatic cystic lesions. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.